MindImmune Extends Series A to $30M to Advance Inflammation-Focused Alzheimer’s Therapy into the Clinic and Appoints Isaac Stoner as CEO

MindImmune 将 A 轮融资扩大至 3000 万美元，以推进聚焦炎症的阿尔茨海默病疗法进入临床，并任命艾萨克·斯托纳为首席执行官。

CAMBRIDGE, Mass., November 24, 2025-- MindImmune Therapeutics, a private company developing new treatments targeting the inflammatory drivers of neurodegenerative disease, today announced two major milestones: the closing of a $10.2 million Series A extension, which brings the total Series A capital raised to $30 million and the appointment of Isaac Stoner as Chief Executive Officer.

马萨诸塞州剑桥市，2025年11月24日——MindImmune Therapeutics是一家私人公司，致力于开发针对神经退行性疾病炎症驱动因素的新疗法。该公司今天宣布了两个重要里程碑：完成了1020万美元的A轮融资扩展，使得A轮融资总额达到3000万美元，并任命艾萨克·斯托纳为首席执行官。

In addition, the company announced that Reetika Bhardwaj of Dolby Family Ventures and Isaac Stoner will join its Board of Directors. MindImmune’s founding CEO Stevin Zorn, PhD, will transition to the role of Chief Scientific Officer..

此外，该公司宣布，杜比家族风险投资公司的里蒂卡·巴尔德瓦杰和艾萨克·斯托纳将加入其董事会。MindImmune 的创始首席执行官斯蒂文·佐恩博士将转任首席科学官。

“Dr. Zorn and his co-founders have made a fundamental discovery that will change how we think about neurodegenerative diseases. MindImmune’s therapeutic programs have the potential to dramatically benefit Alzheimer’s patients by targeting the underlying inflammatory processes that damage synapses and blood vessels in the brain,” said Mr.

“Zorn博士及其共同创始人做出了一个将改变我们对神经退行性疾病认知的基本发现。MindImmune的治疗项目通过针对损害大脑突触和血管的潜在炎症过程，有可能为阿尔茨海默病患者带来显著益处，”先生说道。

Stoner. “I feel fortunate to be leading this talented company as we advance an important first-in-class therapeutic into clinical development.”.

斯通纳。“在我们将这一重要的首创疗法推进到临床开发阶段时，我感到很幸运能够领导这家才华横溢的公司。”

Mr. Stoner brings more than 18 years of experience in life sciences entrepreneurship and company building to MindImmune. He most recently served as entrepreneur-in-residence at Slater Technology Fund and as an advisor and limited partner at KdT Ventures. From 2017 to 2025, he co-founded and led Octagon Therapeutics, serving as CEO for five years.

斯托纳先生为MindImmune带来了超过18年的生命科学创业和公司建设经验。他最近担任了Slater Technology Fund的驻场企业家，以及KdT Ventures的顾问和有限合伙人。从2017年到2025年，他共同创立并领导了Octagon Therapeutics，担任了五年的首席执行官。

Earlier in his career, he held roles at Firefly BioWorks, Ion Torrent Systems, PureTech Health, the Martin Trust Center for MIT Entrepreneurship, Action Potential Venture Capital, and Genome Corp., and co-founded the non-profit Operation Thonapa. He holds a degree in biomedical engineering from Brown University and an MBA from the MIT Sloan School of Management..

早年，他还曾就职于Firefly BioWorks、Ion Torrent Systems、PureTech Health、麻省理工学院创业中心（Martin Trust Center for MIT Entrepreneurship）、Action Potential Venture Capital和Genome Corp，并且共同创立了非营利组织Operation Thonapa。他拥有布朗大学生物医学工程学士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。

The financing was led by Dolby Family Ventures, with participation from Pfizer Ventures, Gates Frontier, Slater Technology Fund, RightHill Ventures, the Foundation for a Better World, and others. Proceeds from the financing will be used to advance the company’s lead candidate, MITI-101, into Phase 1 clinical studies.

本轮融资由杜比家族风险投资公司领投，辉瑞风险投资、盖茨前沿、斯莱特技术基金、RightHill风险投资、美好世界基金会等参与。融资所得将用于推动该公司主要候选药物MITI-101进入一期临床研究。

MITI-101 is a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease progression..

MITI-101是一种单克隆抗体，旨在防止外周免疫细胞进入大脑，并驱动与阿尔茨海默病进展相关的神经炎症。

“We’ve been deeply impressed by the progress MindImmune has made since our initial investment, and we believe that Isaac is well positioned to lead MindImmune as the company grows,” said Reetika Bhardwaj, Principal at Dolby Family Ventures. “The company’s novel approach to modulating neuroinflammation has the potential to change the treatment paradigm for Alzheimer’s and other neurodegenerative diseases.”.

“自从我们最初的投资以来，MindImmune 取得的进展给我们留下了深刻的印象，我们相信 Isaac 有能力在公司成长过程中领导 MindImmune，” Dolby Family Ventures 的负责人 Reetika Bhardwaj 表示。“该公司调节神经炎症的新方法有潜力改变阿尔茨海默病及其他神经退行性疾病的治疗模式。”

About MindImmune Therapeutics

关于MindImmune Therapeutics

MindImmune Therapeutics is a venture-backed biotechnology company developing products that target the immunological drivers of neurodegenerative disease. Its lead program, MITI-101, is designed to block the harmful recruitment of peripheral immune cells into the brain in patients with Alzheimer’s disease and other neurodegenerative conditions.

MindImmune Therapeutics是一家由风险投资支持的生物技术公司，致力于开发针对神经退行性疾病免疫驱动因素的产品。其主要项目MITI-101旨在阻止外周免疫细胞在阿尔茨海默病及其他神经退行性疾病患者中对大脑的有害招募。

By targeting a key upstream mechanism of neuroinflammation, MITI-101 has the potential to deliver a first-in-class therapeutic breakthrough that improves multiple aspects of neurodegeneration. For more information, please visit: www.mindimmune.com..

通过针对神经炎症的一个关键上游机制，MITI-101有潜力提供一种首创的治疗突破，改善神经退行性的多个方面。欲了解更多信息，请访问：www.mindimmune.com。

Contact:

联系：

Media Contact

媒体联系人

Danielle Duchene

丹妮尔·杜舍纳

Inizio Evoke Comms

开始引发通信

Danielle.duchene@inizioevoke.com

丹妮尔·杜切内@英尼齐奥伊沃克.康姆